# NOG

## Overview
The NOG gene encodes the protein noggin, a secreted glycoprotein that functions as a critical antagonist of bone morphogenetic proteins (BMPs). Noggin is characterized by its unique cystine knot topology, which enables it to bind BMPs with high affinity, thereby inhibiting their signaling pathways. This interaction is essential for regulating developmental processes such as skeletogenesis, neural tube formation, and dorsal-ventral patterning in vertebrates (Groppe2002Structural; Zimmerman1996The). Mutations in the NOG gene are linked to several autosomal dominant disorders, including Multiple Synostoses Syndrome and Tarsal-Carpal Coalition Syndrome, highlighting its importance in maintaining normal skeletal and joint development (Marcelino2001Human; Potti2011A). Additionally, aberrant expression of NOG has been implicated in the progression of certain cancers, such as breast cancer bone metastasis, further emphasizing its clinical significance (Tarragona2012Identification).

## Structure
Noggin, encoded by the NOG gene, is a secreted homodimeric glycoprotein with a molecular mass of 64 kDa. Its primary structure consists of 232 amino acids, featuring an acidic amino-terminal half and a cysteine-rich carboxy-terminal half that forms cystine knots (Krause2011Noggin; Marcelino2001Human). The secondary structure includes two pairs of beta-strands extending from a core containing several disulfide bonds, contributing to its stability (Groppe2002Structural). 

The tertiary structure of Noggin is characterized by a cystine knot topology, which is atypical with a 12-membered cystine knot due to an extended CX5C motif, rather than the canonical 10-membered ring (Groppe2002Structural). This structure is crucial for its function as a BMP antagonist, as it allows Noggin to bind BMPs with high affinity, blocking their interaction with receptors (Zimmerman1996The).

Noggin functions as a covalently linked homodimer, indicating a quaternary structure. The dimerization is facilitated by a 'clamp-shaped' structure with two extended 'clip' segments that wrap around BMP ligands, inhibiting their signaling (Groppe2002Structural; Krause2011Noggin). The protein is glycosylated, which may affect its activity and interactions (Krause2011Noggin).

## Function
The NOG gene encodes the protein noggin, which functions as a secreted antagonist of bone morphogenetic proteins (BMPs). Noggin plays a critical role in regulating BMP activity during development, particularly in the formation of the skeletal system. It binds to several BMP family members, including BMP-2, BMP-4, BMP-7, BMP-13, and BMP-14, inhibiting their signaling pathways. This regulation is essential for proper skeletogenesis, as BMPs are involved in recruiting mesenchymal cells, promoting their proliferation and differentiation into chondroblasts and osteoblasts, and inducing apoptosis at future joint sites (Marcelino2001Human).

Noggin's antagonistic action is crucial for proper cell patterning and structure formation, as it prevents excessive BMP signaling that can lead to developmental abnormalities. In vertebrates, noggin is involved in dorsal-ventral patterning and skeletogenesis, ensuring normal development and cellular differentiation processes (Groppe2002Structural). In the neural tube, noggin is necessary for proper growth and patterning, as it prevents premature activation of BMP targets and ensures the survival and proliferation of neural precursors (McMahon1998Noggin-mediated). The protein's role in modulating BMP activity is vital for the development of the neural tube and somites, affecting both dorsal and ventral development (McMahon1998Noggin-mediated).

## Clinical Significance
Mutations in the NOG gene, which encodes the protein noggin, are associated with several autosomal dominant disorders characterized by joint and skeletal abnormalities. These include Multiple Synostoses Syndrome 1 (SYNS1), Tarsal-Carpal Coalition Syndrome (TCC), Stapes Ankylosis with Broad Thumbs and Toes (SABTT), and Brachydactyly Type B2 (BDB2) (Potti2011A). SYNS1 is marked by joint fusions, including hip and vertebral fusions, due to mutations that lead to truncated proteins and loss of noggin secretion (Marcelino2001Human). TCC involves the fusion of carpals, tarsals, and phalanges, linked to specific NOG mutations (Potti2011A). SABTT is characterized by bilateral conductive hearing loss, hyperopia, and broad digits, often caused by nonsense mutations in the NOG gene (Ishino2015Novel). BDB2 is associated with hypoplasia or aplasia of phalanges, although hearing loss is not typically reported (Potti2011A).

Alterations in NOG expression levels have also been implicated in breast cancer bone metastasis, where increased NOG expression enhances the metastatic potential of cancer cells to bone (Tarragona2012Identification). These findings underscore the clinical significance of NOG in both genetic disorders and cancer.

## Interactions
Noggin (NOG) is a secreted protein that interacts with members of the bone morphogenetic protein (BMP) family, primarily acting as an antagonist. It binds directly to BMPs, such as BMP2, BMP4, BMP7, and BMP14, with high affinity, preventing them from interacting with their cell-surface receptors and thereby inhibiting their signaling pathways (Marcelino2001Human; Zimmerman1996The). This interaction is crucial for noggin's role in processes like neural induction and mesoderm dorsalization.

Noggin's binding to BMP4 is highly specific and does not require auxiliary proteins, indicating a direct interaction. The binding affinity between noggin and BMP4 is extremely high, with an apparent Kd of 19 pM, as determined by Scatchard analysis (Zimmerman1996The). Noggin also binds BMP2 with similar affinity, while BMP7 shows reduced affinity, and TGFβ1 does not compete for binding, highlighting noggin's ability to discriminate among related proteins (Zimmerman1996The).

Mutations in noggin can affect its ability to form disulfide-linked dimers, which are necessary for its interaction with BMPs. For instance, certain missense mutations result in decreased dimer formation and secretion efficiency, although mutant noggin proteins can still bind BMPs and retain some functional activity as BMP antagonists (Marcelino2001Human).


## References


[1. (Groppe2002Structural) Jay Groppe, Jason Greenwald, Ezra Wiater, Joaquin Rodriguez-Leon, Aris N. Economides, Witek Kwiatkowski, Markus Affolter, Wylie W. Vale, Juan Carlos Izpisua Belmonte, and Senyon Choe. Structural basis of bmp signalling inhibition by the cystine knot protein noggin. Nature, 420(6916):636–642, December 2002. URL: http://dx.doi.org/10.1038/nature01245, doi:10.1038/nature01245. This article has 411 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/nature01245)

[2. (Ishino2015Novel) Takashi Ishino, Sachio Takeno, and Katsuhiro Hirakawa. Novel nog mutation in japanese patients with stapes ankylosis with broad thumbs and toes. European Journal of Medical Genetics, 58(9):427–432, September 2015. URL: http://dx.doi.org/10.1016/j.ejmg.2015.06.005, doi:10.1016/j.ejmg.2015.06.005. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ejmg.2015.06.005)

[3. (Zimmerman1996The) Lyle B Zimmerman, José M De Jesús-Escobar, and Richard M Harland. The spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell, 86(4):599–606, August 1996. URL: http://dx.doi.org/10.1016/s0092-8674(00)80133-6, doi:10.1016/s0092-8674(00)80133-6. This article has 1292 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s0092-8674(00)80133-6)

[4. (Krause2011Noggin) Carola Krause, Asja Guzman, and Petra Knaus. Noggin. The International Journal of Biochemistry &amp; Cell Biology, 43(4):478–481, April 2011. URL: http://dx.doi.org/10.1016/j.biocel.2011.01.007, doi:10.1016/j.biocel.2011.01.007. This article has 122 citations.](https://doi.org/10.1016/j.biocel.2011.01.007)

[5. (Marcelino2001Human) Jose Marcelino, Christopher M. Sciortino, Michael F. Romero, Lynn M. Ulatowski, R. Tracy Ballock, Aris N. Economides, Peter M. Eimon, Richard M. Harland, and Matthew L. Warman. Human disease-causing nog missense mutations: effects on noggin secretion, dimer formation, and bone morphogenetic protein binding. Proceedings of the National Academy of Sciences, 98(20):11353–11358, September 2001. URL: http://dx.doi.org/10.1073/pnas.201367598, doi:10.1073/pnas.201367598. This article has 72 citations.](https://doi.org/10.1073/pnas.201367598)

[6. (Tarragona2012Identification) Maria Tarragona, Milica Pavlovic, Anna Arnal-Estapé, Jelena Urosevic, Mònica Morales, Marc Guiu, Evarist Planet, Eva González-Suárez, and Roger R. Gomis. Identification of nog as a specific breast cancer bone metastasis-supporting gene. Journal of Biological Chemistry, 287(25):21346–21355, June 2012. URL: http://dx.doi.org/10.1074/jbc.m112.355834, doi:10.1074/jbc.m112.355834. This article has 55 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m112.355834)

[7. (McMahon1998Noggin-mediated) Jill A. McMahon, Shinji Takada, Lyle B. Zimmerman, Chen-Ming Fan, Richard M. Harland, and Andrew P. McMahon. Noggin-mediated antagonism of bmp signaling is required for growth and patterning of the neural tube and somite. Genes &amp; Development, 12(10):1438–1452, May 1998. URL: http://dx.doi.org/10.1101/gad.12.10.1438, doi:10.1101/gad.12.10.1438. This article has 659 citations.](https://doi.org/10.1101/gad.12.10.1438)

[8. (Potti2011A) Tommy A. Potti, Elizabeth M. Petty, and Marci M. Lesperance. A comprehensive review of reported heritable noggin‐associated syndromes and proposed clinical utility of one broadly inclusive diagnostic term:nog‐related‐symphalangism spectrum disorder (nog‐ssd). Human Mutation, 32(8):877–886, June 2011. URL: http://dx.doi.org/10.1002/humu.21515, doi:10.1002/humu.21515. This article has 57 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.21515)